Journal of International Psychiatry

[Abstract] Objective To study the therapeutic efficany of risperidone combined with probiotics in patients with first –onset schizophrenia. Methods 108 patients with first –onset schizophrenia were assigned by randomly digital table method. in two groups, with 54 patients in each group. The observation group received risperidone combined with probiotics, while the control group received risperidone alone, with a treatment cycle of 2 months. The two groups were compared in terms of clinical efficacy, positive symptoms, negative symptoms, cognitive function, NGF , BDNF , NSE , GFAP and adverse reactions. Results There were no significant differences in scores of PANSS scale, CASI scale and serological indexes between the two groups before treatment ;the total effective rate of clinical efficacy and t the score of cognitive ability screening scale (CASI) , NGF , BDNF levels in the observation group were significantly higher than those in the control group, NSE , GFAP levels in the observation group were significantly lower than those in the control group ,the difference was statistically significant (P<0.05). There was no significant difference between the positive symptom score (PANSS positive scale) and the negative symptom score (PANSS negative scale) and the occurrence of adverse reactions in the two groups (P>0.05). Conclusion Risperidone combined with probiotics in the treatment of schizophrenia can improve the total clinical efficiency, improve the cognitive function，brain function and the safety compared with single drug treatment.

Risperidone; Probiotics;Schizophrenia；Therapeutic efficany